Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun;60(6):333-335.
doi: 10.1016/j.arbres.2024.04.006. Epub 2024 Apr 24.

Mortality Risk in Bronchiectasis

[Article in English, Spanish]
Diego J Maselli  1 , Alejandro A Diaz  2
Affiliations
Editorial

Mortality Risk in Bronchiectasis

[Article in English, Spanish]
Diego J Maselli et al. Arch Bronconeumol. 2024 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests

DJM reported personal fees from AstraZeneca, GSK, Amgen, Sanofi/Regeneron. AAD reported personal fees from Boehringer Ingelheim and having a patent for Methods and Compositions Relating to Airway Dysfunction pending (701586–190200USPT).

Figures

Fig. 1.
Fig. 1.
Mortality curve plots by suspected bronchiectasis status across spirometry-based groups. Left upper. Participants with a history of smoking and normal spirometry (defined as FEV1/FVC ratio ≥0.7 and FEV1% predicted ≥80). Right upper. Participants with a history of smoking and preserved ratio impaired spirometry, PRISm (defined as FEV1:FVC ≥0.7 and FEV1% predicted <80). Lower. Participants with a history of smoking and obstructive spirometry (defined as FEV1/FVC <0.7). Data are from a Cox survival model adjusted for age, sex, race, body mass index, smoking status, pack-years smoked, the number of comorbidities, FEV1 after bronchodilator use, oxygen saturation, CT measures of emphysema and airway wall thickness, and CT scanner make/model. Suspected bronchiectasis was defined as more than 1% of bronchi with an airway-to-artery ratio >1 on chest computed tomography scans plus two or more of the following: cough, phlegm, dyspnea, and history of two or more exacerbations. Participants meeting criteria for suspected bronchiectasis (solid black lines) have an increased risk for all-cause mortality compared with those without suspected bronchiectasis (dotted green lines) across the three spirometric groups. Horizontal broken lines mark estimated probabilities of 10-year mortality. Vertical broken lines mark the 10-year follow-up. Pr: probability; CI: confidence interval; PRISM: preserved ratio impaired spirometry; CT: computed tomography; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity.
See this image and copyright information in PMC

References

    1. Sin S, Yun SY, Kim JM, Park CM, Cho J, Choi SM, et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2019;20:271. - PMC - PubMed
    1. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. 2016;2, 00081–2015. - PMC - PubMed
    1. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151:982–92. - PMC - PubMed
    1. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49:1700051. - PubMed
    1. Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, et al. Characterization of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med. 2018;197:1410–20. - PubMed

Publication types